Eight more surgeons approved to use Allied's CardioCel in adults
Eight surgeons, based at The Prince Charles Hospital in Brisbane, were today approved to use Allied Healthcare’s (ASX: AHZ) CardioCel to repair and treat heart defects in adult patients under the Authorised Prescriber Scheme (APS).
CardioCel is a cardiovascular tissue patch used to repair heart deformities, including repairing and reconstructing heart valves. Its properties make it suitable for use by surgeons as a regenerative cardiac repair tissue.
There are now 14 surgeons in Australia that are authorised to use CardioCel for the repair of heart defects. The latest approval, said Allied CEO Lee Rodne, represents “the first department-wide team of cardiac heart surgeons to gain early access to use CardioCel for treating and repairing heart defects in adult patients”.
The product is also making movements overseas: in August, CardioCel received CE mark approval in Europe for use in both children and adults. Allied Healthcare has also filed for marketing approval to the US FDA and hopes for a result next year.
Over 60 patients have successfully received the tissue implant since the initial procedure was performed. Rodne said the adult market “has the potential to significantly expand the market and revenue for the company considerably”.
Allied Healthcare shares were trading 6.41% higher at $0.083 as of 3.30 pm on Tuesday.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
